Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab

Jesús G. Berdeja, Allan Hess, David M. Lucas, Paul O'Donnell, Richard F Ambinder, Louis F. Diehl, Denise Carter-Brookins, Susan Newton, Ian W. Flinn

Research output: Contribution to journalArticle

Abstract

Purpose: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach. Experimental Design: Ten patients received 3 million units/m2 of interleukin-2 (IL-2) i.v. qd on days 1 to 5 and leukapheresed on days 8, 9, and 10. The leukapheresis product was cultured with IL-2 for 48 h to produce LAK cells. Patients then received 375 mg/m2 i.v. rituximab and LAK cells on days 10, 11, and 12. The patients also received 3 million units/m2 of IL-2 i.v. for 5 days starting day 10. For safety purposes, the first three patients did not receive any LAK cell infusions. Results: The LAK cell infusions improved the ADCC activity of peripheral blood lymphocytes compared with pretreatment activity and prevented the decline in ADCC seen after infusion of rituximab alone. Therapy was well tolerated and the most clinically significant toxicities were fever and fatigue. Two patients achieved a partial remission and five had stable disease. Conclusions: The results from these studies suggest that the addition of LAK cells to rituximab augments ADCC in patients with rituximab-refractory lymphoma.

Original languageEnglish (US)
Pages (from-to)2392-2399
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number8
DOIs
StatePublished - Apr 15 2007

Fingerprint

Lymphokine-Activated Killer Cells
Adoptive Transfer
B-Cell Lymphoma
Interleukin-2
Antibodies
Lymphoma
Leukapheresis
Rituximab
Fatigue
Research Design
Fever
Monoclonal Antibodies
Lymphocytes
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. / Berdeja, Jesús G.; Hess, Allan; Lucas, David M.; O'Donnell, Paul; Ambinder, Richard F; Diehl, Louis F.; Carter-Brookins, Denise; Newton, Susan; Flinn, Ian W.

In: Clinical Cancer Research, Vol. 13, No. 8, 15.04.2007, p. 2392-2399.

Research output: Contribution to journalArticle

Berdeja, Jesús G. ; Hess, Allan ; Lucas, David M. ; O'Donnell, Paul ; Ambinder, Richard F ; Diehl, Louis F. ; Carter-Brookins, Denise ; Newton, Susan ; Flinn, Ian W. / Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 8. pp. 2392-2399.
@article{1bf706315d044df895f6e835ffa630b6,
title = "Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab",
abstract = "Purpose: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach. Experimental Design: Ten patients received 3 million units/m2 of interleukin-2 (IL-2) i.v. qd on days 1 to 5 and leukapheresed on days 8, 9, and 10. The leukapheresis product was cultured with IL-2 for 48 h to produce LAK cells. Patients then received 375 mg/m2 i.v. rituximab and LAK cells on days 10, 11, and 12. The patients also received 3 million units/m2 of IL-2 i.v. for 5 days starting day 10. For safety purposes, the first three patients did not receive any LAK cell infusions. Results: The LAK cell infusions improved the ADCC activity of peripheral blood lymphocytes compared with pretreatment activity and prevented the decline in ADCC seen after infusion of rituximab alone. Therapy was well tolerated and the most clinically significant toxicities were fever and fatigue. Two patients achieved a partial remission and five had stable disease. Conclusions: The results from these studies suggest that the addition of LAK cells to rituximab augments ADCC in patients with rituximab-refractory lymphoma.",
author = "Berdeja, {Jes{\'u}s G.} and Allan Hess and Lucas, {David M.} and Paul O'Donnell and Ambinder, {Richard F} and Diehl, {Louis F.} and Denise Carter-Brookins and Susan Newton and Flinn, {Ian W.}",
year = "2007",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-06-1860",
language = "English (US)",
volume = "13",
pages = "2392--2399",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab

AU - Berdeja, Jesús G.

AU - Hess, Allan

AU - Lucas, David M.

AU - O'Donnell, Paul

AU - Ambinder, Richard F

AU - Diehl, Louis F.

AU - Carter-Brookins, Denise

AU - Newton, Susan

AU - Flinn, Ian W.

PY - 2007/4/15

Y1 - 2007/4/15

N2 - Purpose: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach. Experimental Design: Ten patients received 3 million units/m2 of interleukin-2 (IL-2) i.v. qd on days 1 to 5 and leukapheresed on days 8, 9, and 10. The leukapheresis product was cultured with IL-2 for 48 h to produce LAK cells. Patients then received 375 mg/m2 i.v. rituximab and LAK cells on days 10, 11, and 12. The patients also received 3 million units/m2 of IL-2 i.v. for 5 days starting day 10. For safety purposes, the first three patients did not receive any LAK cell infusions. Results: The LAK cell infusions improved the ADCC activity of peripheral blood lymphocytes compared with pretreatment activity and prevented the decline in ADCC seen after infusion of rituximab alone. Therapy was well tolerated and the most clinically significant toxicities were fever and fatigue. Two patients achieved a partial remission and five had stable disease. Conclusions: The results from these studies suggest that the addition of LAK cells to rituximab augments ADCC in patients with rituximab-refractory lymphoma.

AB - Purpose: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach. Experimental Design: Ten patients received 3 million units/m2 of interleukin-2 (IL-2) i.v. qd on days 1 to 5 and leukapheresed on days 8, 9, and 10. The leukapheresis product was cultured with IL-2 for 48 h to produce LAK cells. Patients then received 375 mg/m2 i.v. rituximab and LAK cells on days 10, 11, and 12. The patients also received 3 million units/m2 of IL-2 i.v. for 5 days starting day 10. For safety purposes, the first three patients did not receive any LAK cell infusions. Results: The LAK cell infusions improved the ADCC activity of peripheral blood lymphocytes compared with pretreatment activity and prevented the decline in ADCC seen after infusion of rituximab alone. Therapy was well tolerated and the most clinically significant toxicities were fever and fatigue. Two patients achieved a partial remission and five had stable disease. Conclusions: The results from these studies suggest that the addition of LAK cells to rituximab augments ADCC in patients with rituximab-refractory lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=34247847914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247847914&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1860

DO - 10.1158/1078-0432.CCR-06-1860

M3 - Article

VL - 13

SP - 2392

EP - 2399

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -